Prader-Willi Syndrome: Emerging Therapies
Prader-Willi syndrome is a rare genetic condition characterized by physical and behavioral problems, including an uncontrollable appetite.
A recent approval by regulators for a new medicine to address hyperphagia, or excessive hunger, marks a significant milestone.
This year, the U.S. Food and Drug Administration (FDA) approved VYKAT XR, developed by Soleno Therapeutics, which utilizes diazoxide choline to increase satiety in individuals.
VYKAT XR is now the first and only FDA-approved drug to treat hyperphagia, a notable victory for the Prader-Willi syndrome community.
A common feature of the condition is feeling hungry all the time, and people with Prader-Willi have an uncontrollable appetite.
Several other treatments are currently being trialed, each working differently to address various symptoms of the syndrome.
Author's summary: Prader-Willi syndrome therapies are nearing FDA approval.
More News
- Lando Norris wins his first F1 title despite Max Verstappen victory: Live updates and reaction
- Jay Kelly cast guide: All on which characters George Clooney, Adam Sandler and Laura Dern play in the film
- Kelly Massol : « J’ai réalisé 40% de mon ambition »
- Jack Osbourne breaks silence on jungle feud with Kelly Brook
- Guadeloupean artist Kelly Sinnapah Mary wins French art prize at Art Basel Miami Beach
- Game Preview: Islanders vs Lightning
- How former Gonzaga stars perform in NBA
- Islanders vs. Lightning (Dec 6, 2025) Pregame
- When does 2026 F1 season start?
- Hamilton urges Ferrari to make 'personnel changes' ahead of F1 2026